Literature DB >> 33331095

Crimped monofilament nylon leader for median sternotomy closure in 10 dogs.

Matteo Rossanese1,2, Andrew Tomlinson2.   

Abstract

OBJECTIVE: To describe and report the outcomes after closure of median sternotomies with crimped monofilament nylon leader (MNL) in dogs. STUDY
DESIGN: Retrospective observational study. ANIMALS: Dogs (n = 10) that underwent intrathoracic surgery through a median sternotomy approach.
METHODS: The median sternotomy was closed in a peristernal figure eight pattern with crimped MNL. Medical records were reviewed for clinical and histopathological findings and complications. Owners or veterinarians were contacted to collect long-term follow-up information.
RESULTS: The technique was simple, with no intraoperative complications. Postoperative infection was documented in one dog, requiring removal of a single MNL and associated crimp clamp. Delayed healing of the surgical incision in one dog was managed conservatively. No other complications were documented throughout long-term follow-up at a median of 488 days (range, 199-608).
CONCLUSION: Median sternotomies were successfully closed with crimped MNL and were associated with a low complication rate. CLINICAL SIGNIFICANCE: Crimped MNL represents an alternative method to close median sternotomies in dogs.
© 2020 The American College of Veterinary Surgeons.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33331095     DOI: 10.1111/vsu.13556

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  1 in total

1.  Comparison of median sternotomy closure-related complication rates using orthopedic wire or suture in dogs: A multi-institutional observational treatment effect analysis.

Authors:  Mariette A Pilot; Aaron Lutchman; Julie Hennet; Davina Anderson; William Robinson; Matteo Rossanese; Angelos Chrysopoulos; Jackie Demetriou; Benito De la Puerta; Ronan A Mullins; Hervé Brissot; Nicholas Jeffery; Guillaume Chanoit
Journal:  Vet Surg       Date:  2022-06-28       Impact factor: 1.618

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.